YRGDS Fibronectin Fragment

CAS No. 134282-68-1

YRGDS Fibronectin Fragment( —— )

Catalog No. M30229 CAS No. 134282-68-1

This is a fibronectin fragment, an adhesion peptide that displays strong binding affinity to thrombin-stimulated platelets. It is RGD consisting of sequence.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
100MG Get Quote Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    YRGDS Fibronectin Fragment
  • Note
    Research use only, not for human use.
  • Brief Description
    This is a fibronectin fragment, an adhesion peptide that displays strong binding affinity to thrombin-stimulated platelets. It is RGD consisting of sequence.
  • Description
    This is a fibronectin fragment, an adhesion peptide that displays strong binding affinity to thrombin-stimulated platelets. It is RGD consisting of sequence.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    ——
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    134282-68-1
  • Formula Weight
    596.59
  • Molecular Formula
    C24H36N8O10
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    ——
  • Chemical Name
    Sequence:{Tyr}{Arg}{Gly}{Asp}{Ser}

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

Doherty DE, et al. Fibronectin fragments containing the RGDS cell-binding domain mediate monocyte migration into the rabbit lung. A potential mechanism for C5 fragment-induced monocyte lung accumulation. J Clin Invest. 1990 Oct;86(4):1065-75.
molnova catalog
related products
  • 1H-1-ethyl Candesart...

    1H-1-ethyl Candesartan Cilexetil is a process-related impurity in the bulk synthesis of candesartan cilexetil, which is a potent, long-acting and selective angiotensin II type 1 receptor (AT1) antagonist.

  • Ivermectin B1a

    Ivermectin B1a is the major (80%) component of commercially available ivermectin and a derivative of Avermectin B1a.

  • BCAT-IN-2

    BCAT-IN-2 is an orally active and selective inhibitor of mitochondrial branched-chain aminotransferase (BCATm), inhibits BCATm and BCATc, and is used in obesity and dyslipidemia.